Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Biallelic TP53 alterations predict poorer survival in Mantle Cell Lymphoma: Insights from a national real-world cohort high-touch project

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSean Patrick BlivenUniversity of Alabama at BirminghamXWXiaoyan WangJiangnan UniversityMLMorgan LaelFlatiron Health (United States)

Discussion

Loading...

Member takes

Implication

Observational study finds TP53 mutations worsen outcomes in mantle cell lymphoma, suggesting need for new therapeutic approaches.

Key Points

  • Evaluating the impact of TP53 alterations on overall survival in mantle cell lymphoma patients.
  • Utilized US-based Flatiron Health Research Database for real-world patient data.
  • Analyzed various baseline variables including age, disease subtype, and performance status.
  • Kaplan-Meier curves assessed real-world overall survival across genetic subgroups.
  • Median real-world overall survival was 74.3 months for the entire cohort.
  • Patients with both del17p and TP53 mutations had a median survival of 23 months, the lowest among subgroups.
  • The study highlights the necessity for early molecular testing and prioritization of new therapies for high-risk patients.

Cite This Study

Bliven et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0b5https://doi.org/10.1182/blood-2025-1830
View Full Paper
Ask AI
Bookmark
Share